Mercer Global Advisors’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
Other funds holding ABUS
Mercer Global Advisors's ABUS Position: Q3 2026 in Review
Mercer Global Advisors increased its Arbutus Biopharma (ABUS) stake by 22% in Q3 2026, buying an estimated $19.3K and bringing the position to 22,093 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.
Mercer Global Advisors first reported a position in ABUS in Q4 2024 and has held it in 8 quarters since. The position peaked at $217K in Q4 2025. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.
- Mercer Global Advisors held 22,093 shares of Arbutus Biopharma worth $106K as of Q3 2026.
- Mercer Global Advisors bought 4,008 Arbutus Biopharma shares in Q3 2026, an estimated $19.3K.
- Arbutus Biopharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #3586 holding.
- Mercer Global Advisors first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 8 quarters since.
- Mercer Global Advisors's Arbutus Biopharma position peaked at $217K in Q4 2025.
- 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.